| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 631 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14, 2026 | KYMR Kymera Therapeutics, Inc. | Goodman Noah | Chief Business Officer | Sell | 1,347 | $90.00 | $121,230.00 | -2.6% | - | - | |
| Apr 14, 2026 | GNPX Genprex, Inc. | Longnecker Brent M | Director | Sell | 18 | $1.23 | $22.14 | -0.2% | - | - | |
| Apr 14, 2026 | TVTX Travere Therapeutics, Inc. | Heerma Peter53 | Chief Commercial Officer | Sell | 7,215 | $41.93 | $302,516.29 | -4.9% | - | - | |
| Apr 13, 2026 | IRON Disc Medicine, Inc. | Savage William Jacob55 | Chief Medical Officer | Sell | 5,731 | $66.38 | $380,448.96 | -3.4% | - | - | |
| Apr 13, 2026 | MLYS Mineralys Therapeutics, Inc. | Congleton Jon47 | Chief Executive Officer | Sell | 15,730 | $26.83 | $421,979.27 | -2.2% | - | - | |
| Apr 13, 2026 | ADPT Adaptive Biotechnologies Corporation | Rubinstein Julie84 | President And COO | Sell | 57,180 | $13.26 | $758,108.34 | -2.2% | - | - | |
| Apr 10, 2026 | CGEN Compugen Ltd. | Levine Zurit | SVP, Business Development | Sell | 3,125 | $2.56 | $8,012.50 | -9.6% | - | - | |
| Apr 10, 2026 | NTHI Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | President | Buy | 10,000 | $4.90 | $48,950.00 | +0.3% | - | - | |
| Apr 10, 2026 | XNCR Xencor, Inc. | Cornelissen Bart Jan | Sr. Vice President &CFO | Sell | 3,499 | $12.29 | $42,990.46 | -4.4% | - | - | |
| Apr 10, 2026 | BBIO Bridgebio Pharma, Inc. | Kumar Neil | Chief Executive Officer | Sell | 80,000 | $74.61 | $5,968,780.10 | -0.4% | - | - | |
| Apr 10, 2026 | MEOBF Mesoblast Limited | George Gregory | Director, 10% Owner | Buy | 8,305,962 | $3.15 | $26,135,093.26 | +4.4% | - | - | |
| Apr 10, 2026 | WHWK Whitehawk Therapeutics, Inc. | Ball Bryan | See Remarks | Sell | 56,596 | $3.55 | $201,124.28 | -5.2% | - | - | |
| Apr 10, 2026 | MEOBF Mesoblast Limited | George Gregory | Director, 10% Owner | Buy | 7,910,962 | $1.44 | $11,396,976.86 | +4.2% | - | - | |
| Apr 10, 2026 | VOR Vor Biopharma Inc. | Ra Capital Management, L.P.53 | Director, 10% Owner | Sell | 620,133 | $16.50 | $10,233,811.45 | -3.7% | - | - | |
| Apr 10, 2026 | CGEN Compugen Ltd. | Levine Zurit | SVP, Business Development | Sell | 3,125 | $2.56 | $8,012.50 | -9.6% | - | - | |
| Apr 9, 2026 | WHWK Whitehawk Therapeutics, Inc. | Lennon David James | Chief Executive Officer | Sell | 14,500 | $3.38 | $49,010.00 | -2.7% | - | - | |
| Apr 9, 2026 | MLYS Mineralys Therapeutics, Inc. | Rodman David Malcom56 | Chief Medical Officer | Sell | 2,170 | $27.38 | $59,414.60 | -2.8% | - | - | |
| Apr 9, 2026 | PHVS Pharvaris N.V. | Modig Berndt | Chief Executive Officer | Sell | 23,333 | $27.74 | $647,281.38 | -7.6% | - | - | |
| Apr 9, 2026 | NTHI Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | President | Buy | 15,000 | $5.47 | $82,000.00 | +0.2% | - | - | |
| Apr 9, 2026 | RLAY Relay Therapeutics, Inc. | Catinazzo Thomas71 | Chief Financial Officer | Sell | 19,517 | $13.19 | $257,498.17 | -4.4% | - | - | |
| Apr 9, 2026 | NTHI Neonc Technologies Holdings, Inc. | Suh, David Jr. | Chief Accounting Officer | Buy | 200 | $5.00 | $1,000.00 | +0.2% | - | - | |
| Apr 8, 2026 | ADPT Adaptive Biotechnologies Corporation | Lo Francis79 | Chief People Officer | Sell | 22,564 | $15.07 | $340,039.48 | -7.7% | - | - | |
| Apr 8, 2026 | APGE Apogee Therapeutics, Inc. | Henderson Michael Thomas58 | Chief Executive Officer | Sell | 20,000 | $82.58 | $1,651,664.00 | -0.6% | - | - | |
| Apr 8, 2026 | TARA Protara Therapeutics, Inc. | Zummo Jacqueline | Chief R&D Officer | Sell | 1,134 | $5.40 | $6,123.60 | -1.2% | - | - | |
| Apr 8, 2026 | BEIGF Beone Medicines AG | Lee Chan Henry47 | SVP, General Counsel | Sell | 332 | $311.59 | $103,447.88 | -100% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.